Melanoma

he following list provides a brief description of skin cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.

Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.

Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.

 

Illuminate-301

Registered Title A Randomized Phase 3 Comparison of IMO-2125 with Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma Ipilimumab versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma
Purpose  A Phase 3 global, multi-center, open-label comparison of ipilimumab with and without intratumoral IMO-2125 in subjects with advanced melanoma who had confirmed disease progression while on nivolumab or pembrolizumab
Lay Summary  N/A
WA Trial Sites

FSH - Cancer Centre Clinical Trials Unit (08) 615 26530

Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

Imspire 170

Registered Title

A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma

Purpose

This is a Phase III, multicenter, open-label, randomized study designed to evaluate the efficacy, safety, and pharmacokinetics of cobimetinib plus atezolizumab compared with pembrolizumab in treatment-naive participants with advanced BRAFV600 wild-type melanoma.

Lay Summary

N/A

WA Trial Sites

Fiona Stanley Hospital Logo

Cancer Centre Clinical Trials Unit
Caroline Stone
Clinical Trials Manager
Phone 08 615 26530 Fax 08 615 20954
caroline.stone@health.wa.gov.au

Links

US National Library of Medicine

Acknowledgements: US National Library of Medicine


PISCES

Registered title
A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment 
 Purpose
 Lay title
This will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on pembrolizumab or nivolumab.
 WA trial Sites

 

 Affinity Clinical Research (08) 9446 8726

 

St John of God - Subiaco (08) 6465 9204

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

CPDR001F2301

Registered Title
 A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
 Purpose  
 Lay Summary
 To evaluate the safety and efficacy of the combination of an anti-PD-1 antibody (Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma
 WA Trial Sites

SCGH - Medical Oncology (08) 6383 3000

 Links US National Library of Medicine

Acknowledgements: US National Library of Medicine


IMP321-P012 / TACTI-mel

Not Currently Recruiting

Registered Title A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab 
 Purpose  The purpose of this study is to determine the safety, tolerability and recommended phase 2 dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients with unresectable or metastatic melanoma.
 Lay Summary  N/A
 
WA Trial Sites

FSH - Cancer Centre Clinical Trials Unit (08) 615 26530 

 Links  
US National Library of Medicine

Acknowledgements: US National Library of Medicine


CA224-047

Registered Title A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma 
 
Purpose
 The purpose of this study is to determine whether nivolumab in combination with relatlimab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread

 Lay Summary  N/A
 WA Trial Sites

FSH - Cancer Centre Clinical Trials Unit (08) 615 26530

 Links  US National Library of Medicine

Acknowledgements: US National Library of Medicine

 

 

 

 

 

[Return to List of Clinical Trials]